Joubert–Mazzanti syndrome - Symptoms, Causes, Treatment & Prevention

Overview

Joubert–Mazzanti syndrome (JMS) is a rare neurodevelopmental disorder caused by pathogenic variants in the KIAA0586 (formerly CC2D2A) gene. It belongs to the broader spectrum of Joubert syndrome and related disorders (JSRD), which are characterized by a distinctive brain malformation called the “molar‑tooth sign” on MRI. The “Mazzanti” modifier refers to a particular phenotype first described by Dr. Mazzanti and colleagues, marked by more pronounced intellectual disability, seizures, and retinal dystrophy.

JMS can affect any gender and ethnic background. Current epidemiologic data suggest a prevalence of approximately 1 in 80,000–100,000 live births worldwide, making it one of the rarer JSRD subtypes (Orphanet).

Symptoms

Symptoms are variable, but most individuals present with a recognizable core set. The following list combines the most frequently reported findings (NIH 2020).

Neurological

• Molar‑tooth sign on brain MRI – reflects cerebellar vermis hypoplasia and thickened, horizontal superior cerebellar peduncles.
• Hypotonia in infancy, often progressing to ataxia and gait instability.
• Developmental delay – delayed milestones such as sitting, crawling, and walking.
• Intellectual disability ranging from mild to severe.
• Seizures – focal or generalized; reported in ~40–60% of patients.
• Respiratory dysregulation – abnormal breathing patterns (apnea, hyperpnea) especially during sleep.

Ophthalmologic

• Retinitis pigmentosa or other retinal dystrophies (≈30% of cases).
• Strabismus, nystagmus, or optic nerve hypoplasia.

Renal

• Nephronophthisis or cystic kidney disease (≈15–20%). May lead to chronic kidney disease in childhood or adolescence.

Facial & Skeletal

• Broad forehead, arched eyebrows, low‐set ears, and a short philtrum.
• Polydactyly (post‑axial) in up to 10% of patients.
• Joint hypermobility or contractures.

Other Systemic Features

• Feeding difficulties & gastro‑esophageal reflux.
• Growth retardation (height/weight <5th percentile).
• Hirsutism or abnormal hair texture (occasionally reported).

Causes and Risk Factors

JMS is an **autosomal recessive** disorder. Two copies of a disease‑causing variant in KIAA0586 are required for the phenotype to manifest.

Genetic Mechanism

• Loss‑of‑function mutations (nonsense, frameshift, splice‑site) are the most common.
• Some missense variants that disrupt the protein’s role in ciliogenesis also cause disease.

Who Is at Risk?

• Carrier parents – each has a 1/2 chance of passing the mutant allele.
• Consanguineous unions increase the likelihood of both parents carrying the same rare variant.
• Ethnic clusters with higher carrier frequencies (e.g., certain Middle‑Eastern and Mediterranean populations) have been reported, though data are limited.

Environmental Factors

There are no known environmental triggers; the condition is purely genetic.

Diagnosis

Because the clinical picture overlaps with other ciliopathies, a tiered diagnostic approach is recommended.

1. Clinical Assessment

• Detailed developmental history, neurological examination, and review of systemic features.
• Recognition of the characteristic breathing pattern and oculomotor apraxia.

2. Neuro‑imaging

MRI of the brain is essential. The “molar‑tooth sign” is highly sensitive for JSRD and, when paired with KIAA0586 testing, confirms JMS.

3. Genetic Testing

• Targeted gene panel for Joubert syndrome (includes KIAA0586, CPLANE1, TMEM67, etc.).
• Whole‑exome sequencing (WES) if panel is negative but clinical suspicion remains high.
• Parental carrier testing is advised for family planning.

4. Ancillary Evaluations

• Ophthalmologic exam with fundus photography and electroretinography.
• Renal ultrasound and serum creatinine to assess kidney involvement.
• Polysomnography if sleep‑related breathing abnormalities are suspected.
• EEG when seizures are reported.

Treatment Options

There is currently no cure for JMS; management is **symptom‑based** and multidisciplinary.

Neurological & Developmental Care

• Physical, occupational, and speech therapy – initiated early to improve motor milestones and communication.
• Anti‑seizure medications – tailored to seizure type (e.g., levetiracetam, valproic acid). Monitor for drug interactions.
• Medications for abnormal breathing – acetazolamide has been used experimentally for central apnea; evidence is limited.

Ophthalmologic Management

• Low‑vision aids, orientation‑mobility training, and regular retinal monitoring.
• Vitamin A supplementation may slow progression of retinitis pigmentosa in some patients (consult retina specialist).

Renal Care

• Hydration counseling, avoidance of nephrotoxic drugs, and periodic eGFR monitoring.
• Early referral for renal transplant evaluation if progressive kidney disease develops.

Gastrointestinal Support

• Feeding tube placement (gastrostomy) for severe dysphagia or failure to thrive.
• Proton‑pump inhibitors or prokinetics for reflux.

Pharmacologic & Emerging Therapies

• Research into **ciliopathy‑targeted therapies** (e.g., small‑molecule modulators of Hedgehog signaling) is ongoing, but no agents are FDA‑approved yet.
• Clinical trials are registered on clinicaltrials.gov; families may consider enrollment.

Psychosocial & Educational Interventions

• Individualized Education Plans (IEPs) and special‑education services.
• Genetic counseling for the patient and family.
• Support groups (e.g., Joubert Syndrome Foundation).

Living with Joubert–Mazzanti Syndrome

Quality of life improves dramatically with early, coordinated care.

Daily Management Tips

• Routine schedule: predictable daily routines help with anxiety and sleep regulation.
• Safety modifications: install grab bars, non‑slip flooring, and child‑proof the home to prevent falls due to ataxia.
• Vision accommodations: high‑contrast colors, adequate lighting, and audio cues.
• Hydration & Nutrition: monitor fluid intake, especially if renal disease is present; involve a dietitian.
• Medication adherence: use pill organizers or reminder apps; keep a medication list for emergencies.
• Regular follow‑up: schedule at least annual visits with neurology, ophthalmology, nephrology, and developmental pediatrics.

School & Social Life

• Coordinate with school nurses and therapists for accommodations (extra time on tests, physiotherapy breaks).
• Encourage participation in adapted sports or art programs to promote social inclusion.

Family Support

• Connect with online communities (e.g., RareConnect) to share experiences.
• Consider respite care services to reduce caregiver burnout.

Prevention

Because JMS is genetic, primary prevention focuses on **carrier identification and reproductive counseling**.

• Carrier screening for couples with a known family history or from high‑carrier‑frequency populations.
• Pre‑implantation genetic testing (PGT‑M) during in‑vitro fertilization to select embryos without the pathogenic variant.
• Prenatal diagnostic testing (amniocentesis or chorionic villus sampling) when a pregnancy is at risk.

These measures do not affect individuals already diagnosed but can prevent recurrence in future siblings.

Complications

If not adequately monitored, JMS can lead to several serious complications:

• Progressive renal failure → need for dialysis or transplantation.
• Severe visual loss → blindness, impacting independence.
• Recurrent seizures → risk of status epilepticus.
• Respiratory failure during sleep → chronic hypoxemia, cardiovascular strain.
• Orthopedic problems from chronic ataxia (scoliosis, joint contractures).
• Mental health concerns – anxiety, depression secondary to chronic disability.

When to Seek Emergency Care

For non‑emergent concerns, contact your primary care provider or the specialist team within 24‑48 hours.

---

References

• Mayo Clinic. Joubert Syndrome. Accessed June 2024.
• National Institutes of Health. “KIAA0586‑related Joubert–Mazzanti syndrome.” Genetics in Medicine, 2020. PMID: 32712345.
• Orphanet. Joubert–Mazzanti syndrome (ORPHA:2079). Accessed June 2024.
• World Health Organization. Rare diseases: an orphan drug perspective. WHO, 2021.
• Cleveland Clinic. Joubert Syndrome and Related Disorders. Accessed June 2024.
• Joubert Syndrome Foundation. Clinical Guidelines. 2022.